With a Trump-driven reduction of nearly 2,000 employees, agency officials view artificial intelligence as a way to speed drugs to the market.
Category: Regulation and Deregulation of Industry
-
As Energy Costs Surge, Eastern Governors Blame a Grid Manager
Anger at PJM, which manages the electrical grid in all or parts of 13 states and the District of Columbia, has been boiling over in some state capitals.
-
‘Ruinous Burdens’: Border Businesses Struggle Under Trump’s Cartel Crackdown
Federal judges have lauded the government’s goal of rooting out money laundering schemes but questioned the effectiveness of a tactic that’s wreaking havoc on small money services operations.
-
How Trump Has Gained the Upper Hand Over Musk
But Mr. Trump’s warnings to his former ally are backed by several ways the White House could punish the world’s richest man.
-
The Rich Compensation for Being the C.E.O.
The chief executives at Palantir, which scoops up data for the government, and Veeva Systems, a cloud-computing company, topped two lists of the highest-paid C.E.O.s.
-
As Trump’s Tariffs Reshape Trade, Businesses Struggle With Economic Uncertainty
Policymakers and business owners are navigating a highly uncertain moment for the economy, wary of overreacting but watchful of a meaningful downturn.
-
How ASML, a Key Supplier to the Chip Industry, Is Navigating Trump’s Trade War
ASML, the Dutch company that makes multimillion-dollar tools to manufacture advanced semiconductors, is grappling with the repercussions of a tech trade war.
-
Four States Ask F.D.A. to Lift Special Restrictions on Abortion Pill
The states consider it a move to force the F.D.A. to review and acknowledge extensive research showing the pill’s safety.
-
Kennedy Says ‘Charlatans’ Are No Reason to Block Unproven Stem Cell Treatments
The U.S. health secretary said people should have access to experimental therapies including unregulated stem cells. But some methods have resulted in blindness, tumors and other injuries.
